Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR

British Journal of Haematology

Volumn 166, Issue 3, 2014, Pages 360-368

  Raponi, Sara ^a   Della Starza, Irene ^a   De Propris, Maria S ^a   Del Giudice, Ilaria ^a   Mauro, Francesca R ^a   Marinelli, Marilisa ^a   Di Maio, Valeria ^a   Piciocchi, Alfonso ^b   Foà, Robin ^a   Guarini, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Foundation   (Italy)

Author keywords

ASO IgH RQ PCR; Chronic lymphocytic leukaemia; Flow cytometry; Minimal residual disease

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; OLIGONUCLEOTIDE;

ALLELE SPECIFIC OLIGONUCLEOTIDE IMMUNOGLOBULIN HEAVY CHAIN REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SENSIBILITY; SURVIVAL TIME;

ASO IGH RQ-PCR; CHRONIC LYMPHOCYTIC LEUKAEMIA; FLOW CYTOMETRY; MINIMAL RESIDUAL DISEASE;

ALLELES; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84904051707     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12887     Document Type: Article

References (25)

1. Böttcher, S., Ritgen, M., Pott, C., Brüggemann, M., Raff, T., Stilgenbauer, S., Döhner, H., Dreger, P. & Kneba, M. (2004) Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia, 18, 1637-1645.
2. Böttcher, S., Stilgenbauer, S., Busch, R., Brüggemann, M., Raff, T., Pott, C., Fischer, K., Fingerle-Rowson, G., Döhner, H., Hallek, M., Kneba, M. & Ritgen, M. (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia, 23, 2007-2017.
3. Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R.M., Fingerle-Rowson, G., Fink, A.M., Bühler, A., Zenz, T., Wenger, M.K., Mendila, M., Wendtner, C.M., Eichhorst, B.F., Döhner, H., Hallek, M.J. & Kneba, M. (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. Journal of Clinical Oncology, 30, 980-988.
4. Brochet, X., Lefranc, M.P. & Giudicelli, V. (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Research, 36 (Web Server issue), 503-508.
5. Brüggemann, M., Gökbuget, N. & Kneba, M. (2012) Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Seminars in Oncology, 39, 47-57.
6. Cazzaniga, G. & Biondi, A. (2005) Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica, 90, 382-390.
7. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
8. Durrieu, F., Geneviève, F., Arnoulet, C., Brumpt, C., Capiod, J.C., Degenne, M., Feuillard, J., Garand, R., Kara-Terki, A., Kulhein, E., Maynadié, M., Ochoa-Noguera, M.E., Plesa, A., Roussel, M., Eghbali, H., Truchan-Graczyk, M., de Carvalho Bittencourt, M., Feugier, P. & Béné, M.C. (2011) Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up - a GEIL-GOELAMS study. Cytometry. Part B, Clinical Cytometry, 80, 346-353.
9. Garand, R., Beldjord, K., Cavé, H., Fossat, C., Arnoux, I., Asnafi, V., Bertrand, Y., Boulland, M.L., Brouzes, C., Clappier, E., Delabesse, E., Fest, T., Garnache-Ottou, F., Huguet, F., Jacob, M.C., Kuhlein, E., Marty-Grès, S., Plesa, A., Robillard, N., Roussel, M., Tkaczuk, J., Dombret, H., Macintyre, E., Ifrah, N., Béné, M.C. & Baruchel, A. (2013) Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia, 27, 370-376.
10. Ghia, P. (2012) A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? Hematology, 2012, 97-104.
11. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J., International Workshop on Chronic Lymphocytic Leukemia. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
12. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H. & Stilgenbauer, S., International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
13. Jilani, I., O'Brien, S., Manshuri, T., Thomas, D.A., Thomazy, V.A., Imam, M., Naeem, S., Verstovsek, S., Kantarjian, H., Giles, F., Keating, M. & Albitar, M. (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 102, 3514-3520.
14. Lefranc, M.P. (2009) Antibody databases: IMGT, a French platform of world-wide interest. Médecine Sciences, 25, 1020-1023.
15. Moreno, C., Villamor, N., Colomer, D., Esteve, J., Giné, E., Muntañola, A., Campo, E., Bosch, F. & Montserrat, E. (2006) Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 107, 4563-4569.
16. Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology, 23, 2971-2979.
17. Neale, G.A., Coustan-Smith, E., Pan, Q., Chen, X., Gruhn, B., Stow, P., Behm, F.G., Pui, C.H. & Campana, D. (1999) Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia, 13, 1221-1226.
18. Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 29-35.
19. Rawstron, A.C., de Tute, R., Jack, A.S. & Hillmen, P. (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia, 20, 2102-2110.
20. Rawstron, A.C., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J.L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., Evans, P.A., Natkunam, Y., Coutre, S.E., Avery, E.D., Rassenti, L.Z., Kipps, T.J., Caligaris-Cappio, F., Kneba, M., Byrd, J.C., Hallek, M.J., Montserrat, E. & Hillmen, P. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia, 21, 956-964.
21. Rawstron, A.C., Böttcher, S., Letestu, R., Villamor, N., Fazi, C., Kartsios, H., de Tute, R.M., Shingles, J., Ritgen, M., Moreno, C., Lin, K., Pettitt, A.R., Kneba, M., Montserrat, E., Cymbalista, F., Hallek, M., Hillmen, P. & Ghia, P., European Research Initiative in CLL. (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia, 27, 142-149.
22. Sartor, M.M. & Gottlieb, D.J. (2013) A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytometry. Part B, Clinical Cytometry, 84, 96-103.
23. Uhrmacher, S., Erdfelder, F. & Kreuzer, K.A. (2010) Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia. Advances in Hematology, 2010, 1-11.
24. van der Velden, V.H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E. & van Dongen, J.J., European Study Group on MRD detection in ALL (ESG-MRD-ALL). (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604-611.
25. Voena, C., Ladetto, M., Astolfi, M., Provan, D., Gribben, J.G., Boccadoro, M., Pileri, A. & Corradini, P. (1997) A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia, 11, 1793-1798.